BluCon Biotech and LG Chem enter into unique investment agreement
BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market
Advertisement
BluCon Biotech, a German biotech company, and LG Chem, a Korean chemical company, have entered into an investment agreement to scale up and commercialize BluCon Biotech’s proprietary technology to supplement LG Chem´s bio-economy portfolio BluCon Biotech’s technology has the potential to be a disruptive game changer in the world's plastics market by using direct fermentation of lignocellulosic feedstock to lactic acid to achieve bioplastic PLA that is price-competitive with fossil-based plastics, contributing to a sustainable circular bio-economy. BluCon Biotech and LG Chem agreed to work together on a novel process for converting non-food lignocellulosic feedstocks into high purity lactic acid, a precursor for bio-based and biodegradable plastics.
BluCon plans to adapt its process for the conversion of feedstocks, such as wheat straw into bioplastics, to other feedstocks such as corn stover, bagasse, cotton stalks, starch and algae (symbolic image).
Computer-generated image
“BluCon's IP-protected technology is highly efficient and unique as it is the first in the world to directly ferment ligno-cellulosic biomass to lactic acid in one bioreactor. This will lead to a commercially viable process that can produce lactic acid at a lower cost than traditional methods, making bio-based plastics competitive with fossil-based plastics.” says Co-Founder and Co-CEO Dr. Albrecht Läufer.
By using non-food feedstocks derived from agricultural residues and waste streams e.g. from the pulp and paper industry, BluCon not only avoids competition of chemical production with the food chain, it also helps to protect the environment by reducing pollution from incineration of straw or bagasse and avoiding CO2 emissions.
BluCon has already received funding from the German Ministry of Economics and Climate Protection to scale up its proprietary fermentation technology. The company is currently performing pilot runs. “We are proud to have won the investment and support of LG Chem, one of the major chemical companies in the world, that clearly commits to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050.” says Co-Founder and Co-CEO Markus Fehr.
BluCon plans to adapt its process for the conversion of feedstocks, such as wheat straw into bioplastics, to other feedstocks such as corn stover, bagasse, cotton stalks, starch and algae. BluCon will serve as a technology supplier. It will license its technologies to investors, the chemical and biotech industry and to large feedstock and bioplastic producers. This will generate revenue through milestone, royalty and service fees. The factories will likely be located in areas with ample feedstock supplies. This can con-tribute to bring development to remote rural areas worldwide. Additionally, the technology platform of BluCon has the flexibility to be used to produce other bio-based products as well, such as ethanol or succinic acid.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests - Addition of 70 assays enables the company to offer a complete workflow in food testing and to strengthen its fastest growing business segment
Affymetrix Selects Singapore For Its First Manufacturing Facility Outside The United States
Rapid test for the determination of antibodies against Sars-Cov-2 - No elaborate biosafety precautions are necessary
Chemists report nicotine-chomping bacteria may hold key to anti-smoking therapy
Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection - Research offers a 'cautionary tale' for the development of CD4 T cell vaccines
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b
Merck Plans to Invest € 1 Billion at the Darmstadt Site - Employment guarantee extended until the end of 2025
